[The gamma-linolenic acid (GLA)--the therapeutic value].
The essential fatty acid deficiency (EFA) gives rise to many pathologic states and may predispose for certain disease development. One of the most frequently deficient EFA is gamma-linolenic acid. The gamma-linolenic acid supplementation brings some hopeful effects in treatment of diabetic neuropathy, eczema, cyclic mastalgia, rheumatoid arthritis, osteoporosis and ADHD. Many double blind trials have been performed for defective assessment of GLA efficiency. Some of them have proved statistically significant efficacy, the others have led to some doubts. There is a necessity to perform more trials. The gamma-linolenic acid is completely safe, non-toxic, and non-cancerogenic substance. It can be an interesting alternative for supporting treatment.
Dobryniewski
Jacek
J
Oddzial III Ogólnopsychiatryczny z Pododdziałem Psychogeriatrii SPPZOZ w Choroszczy. j.dobryniewski@vp.pl
Szajda
Sławomir Dariusz
SD
Waszkiewicz
Napoleon
N
Zwierz
Krzysztof
K
D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D003929:Diabetic Neuropathies / Q000188:drug therapy*; D019587:Dietary Supplements; D004485:Eczema / Q000188:drug therapy*; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D016896:Treatment Outcome; D017965:gamma-Linolenic Acid / Q000627:therapeutic use*
D017965:gamma-Linolenic Acid